Skip to main content
Top
Published in: The Journal of Headache and Pain 1/2019

Open Access 01-12-2019 | Migraine | Research article

Migraine and cluster headache show impaired neurosteroids patterns

Authors: Angela Koverech, Claudia Cicione, Luana Lionetto, Marta Maestri, Francesco Passariello, Elisabetta Sabbatini, Matilde Capi, Cristiano Maria De Marco, Martina Guglielmetti, Andrea Negro, Luisa Di Menna, Maurizio Simmaco, Ferdinando Nicoletti, Paolo Martelletti

Published in: The Journal of Headache and Pain | Issue 1/2019

Login to get access

Abstract

Background

Perturbation of neuronal excitability contributes to migraine. Neurosteroids modulate the activity of γ-aminobutyric acid A and N-methyl-d-aspartate receptors, and might be involved in the pathogenesis of migraine. Here, we measured plasma levels of four neurosteroids, i.e., allopregnanolone, epiallopregnanolone, dehydroepiandrosterone and deydroepiandrosterone sulfate, in patients affected by episodic migraine, chronic migraine, or cluster headache.

Methods

Nineteen female patients affected by episodic migraine, 51 female patients affected by chronic migraine, and 18 male patients affected by cluster headache were recruited to the study. Sex- and age-matched healthy control subjects (31 females and 16 males) were also recruited. Patients were clinically characterized by using validated questionnaires. Plasma neurosteroid levels were measured by liquid chromatography-tandem mass spectrometry.

Results

We found disease-specific changes in neurosteroid levels in our study groups. For example, allopregnanolone levels were significantly increased in episodic migraine and chronic migraine patients than in control subjects, whereas they were reduced in patients affected by cluster headache. Dehydroepiandrosterone and dehydroepiandrosterone sulfate levels were reduced in patients affected by chronic migraine, but did not change in patients affected by cluster headache.

Conclusion

We have shown for the first time that large and disease-specific changes in circulating neurosteroid levels are associated with chronic headache disorders, raising the interesting possibility that fluctuations of neurosteroids at their site of action might shape the natural course of migraine and cluster headache. Whether the observed changes in neurosteroids are genetically determined or rather result from exposure to environmental or intrinsic stressors is unknown. This might also be matter for further investigation because stress is a known triggering factor for headache attacks in both migraineurs and cluster headache patients.
Literature
1.
go back to reference GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1545–1602CrossRef GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1545–1602CrossRef
2.
go back to reference Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z (2018) Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 19:17CrossRef Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z (2018) Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 19:17CrossRef
3.
go back to reference May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12:455–464CrossRef May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12:455–464CrossRef
4.
go back to reference Reddy DS, Estes WA (2016) Clinical potential of neurosteroids for CNS disorders. Trends Pharmacol Sci 37:543–561CrossRef Reddy DS, Estes WA (2016) Clinical potential of neurosteroids for CNS disorders. Trends Pharmacol Sci 37:543–561CrossRef
5.
go back to reference Hosie AM, Wilkins ME, Smart TG (2007) Neurosteroid binding sites on GABAA receptors. Pharmacol Ther 116:7–19CrossRef Hosie AM, Wilkins ME, Smart TG (2007) Neurosteroid binding sites on GABAA receptors. Pharmacol Ther 116:7–19CrossRef
6.
go back to reference Friess E, Schiffelholz T, Steckler T, Steiger A (2000) Dehydroepiandrosterone-a neurosteroid. Eur J Clin Investig 30(suppl.:46–50CrossRef Friess E, Schiffelholz T, Steckler T, Steiger A (2000) Dehydroepiandrosterone-a neurosteroid. Eur J Clin Investig 30(suppl.:46–50CrossRef
7.
go back to reference Naylor JC, Kilts JD, Strauss JL, Szabo ST, Dunn CE, Wagner HR et al (2016) An exploratory pilot investigation of neurosteroids and self-reported pain in female Iraq/Afghanistan-era veterans. J Rehabil Res Dev 53:499–510CrossRef Naylor JC, Kilts JD, Strauss JL, Szabo ST, Dunn CE, Wagner HR et al (2016) An exploratory pilot investigation of neurosteroids and self-reported pain in female Iraq/Afghanistan-era veterans. J Rehabil Res Dev 53:499–510CrossRef
8.
go back to reference Taubøll E, Sveberg L, Svalheim S (2015) Interactions between hormones and epilepsy. Seizure 28:3–11CrossRef Taubøll E, Sveberg L, Svalheim S (2015) Interactions between hormones and epilepsy. Seizure 28:3–11CrossRef
9.
go back to reference Reddy DS (2014) Neurosteroids and their role in sex-specific epilepsies. Neurobiol Dis (Pt. B) 72:198–209CrossRef Reddy DS (2014) Neurosteroids and their role in sex-specific epilepsies. Neurobiol Dis (Pt. B) 72:198–209CrossRef
10.
go back to reference Pietrobon D, Striessnig J (2003) Neurobiology of migraine. Nat Rev Neurosci 5:386–398CrossRef Pietrobon D, Striessnig J (2003) Neurobiology of migraine. Nat Rev Neurosci 5:386–398CrossRef
11.
go back to reference Pietrobon D, Moskowitz MA (2014) Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations. Nat Rev Neurosci 6:379–393CrossRef Pietrobon D, Moskowitz MA (2014) Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations. Nat Rev Neurosci 6:379–393CrossRef
12.
go back to reference Aguila ME, Rebbeck T, Leaver AM, Lagopoulos J, Brennan PC, Hübscher M et al (2016) The association between clinical characteristics of migraine and brain GABA levels: an exploratory study. J Pain 17:1058–1067CrossRef Aguila ME, Rebbeck T, Leaver AM, Lagopoulos J, Brennan PC, Hübscher M et al (2016) The association between clinical characteristics of migraine and brain GABA levels: an exploratory study. J Pain 17:1058–1067CrossRef
13.
go back to reference Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:629–808CrossRef Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:629–808CrossRef
14.
go back to reference Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12:575–583CrossRef Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12:575–583CrossRef
15.
go back to reference Martelletti P (2018) The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine. J Headache Pain 19:2CrossRef Martelletti P (2018) The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine. J Headache Pain 19:2CrossRef
16.
go back to reference Negro A, Martelletti P (2011) Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain 12:593–601CrossRef Negro A, Martelletti P (2011) Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain 12:593–601CrossRef
17.
go back to reference Lionetto L, De Andrés F, Capi M, Curto M, Sabato D, Simmaco M et al (2017) LC-MS/MS simultaneous analysis of allopregnanolone, epiallopregnanolone, pregnanolone, dehydroepiandrosterone and dehydroepiandrosterone 3-sulfate in human plasma. Bioanalysis 9:527–539CrossRef Lionetto L, De Andrés F, Capi M, Curto M, Sabato D, Simmaco M et al (2017) LC-MS/MS simultaneous analysis of allopregnanolone, epiallopregnanolone, pregnanolone, dehydroepiandrosterone and dehydroepiandrosterone 3-sulfate in human plasma. Bioanalysis 9:527–539CrossRef
18.
go back to reference Guennoun R, Labombarda F, Gonzalez Deniselle MC, Liere P, De Nicola AF, Schumacher M (2015) Progesterone and allopregnanolone in the central nervous system: response to injury and implication for neuroprotection. J Steroid Biochem Mol Biol 146:48–61CrossRef Guennoun R, Labombarda F, Gonzalez Deniselle MC, Liere P, De Nicola AF, Schumacher M (2015) Progesterone and allopregnanolone in the central nervous system: response to injury and implication for neuroprotection. J Steroid Biochem Mol Biol 146:48–61CrossRef
19.
20.
go back to reference Wang MD, Bäckström T, Landgren S (2000) The inhibitory effects of allopregnanolone and pregnanolone on the population spike, evoked in the rat hippocampal CA1 stratum pyramidale in vitro, can be blocked selectively by epiallopregnanolone. Acta Physiol Scand 169:333–341CrossRef Wang MD, Bäckström T, Landgren S (2000) The inhibitory effects of allopregnanolone and pregnanolone on the population spike, evoked in the rat hippocampal CA1 stratum pyramidale in vitro, can be blocked selectively by epiallopregnanolone. Acta Physiol Scand 169:333–341CrossRef
21.
go back to reference Sutherland HG, Griffiths LR (2017) Genetics of migraine: insights into the molecular basis of migraine disorders. Headache 57:537–569CrossRef Sutherland HG, Griffiths LR (2017) Genetics of migraine: insights into the molecular basis of migraine disorders. Headache 57:537–569CrossRef
22.
go back to reference Biagini G, Rustichelli C, Curia G, Vinet J, Lucchi C, Pugnaghi M et al (2013) Neurosteroids and epileptogenesis. J Neuroendocrinol 25:980–990CrossRef Biagini G, Rustichelli C, Curia G, Vinet J, Lucchi C, Pugnaghi M et al (2013) Neurosteroids and epileptogenesis. J Neuroendocrinol 25:980–990CrossRef
23.
go back to reference Belelli D, Lambert JJ (2005) Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 7:565–575CrossRef Belelli D, Lambert JJ (2005) Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 7:565–575CrossRef
24.
go back to reference Limmroth V, Lee WS, Moskowitz MA (1996) GABAA-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges. Br J Pharmacol 117:99–104CrossRef Limmroth V, Lee WS, Moskowitz MA (1996) GABAA-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges. Br J Pharmacol 117:99–104CrossRef
25.
go back to reference Holsboer F, Grasser A, Friess E, Wiedemann K. Steroid effects on central neurons and implications for psychiatric and neurological disorders. Ann N Y Acad Sci. 1994;746:345–59.CrossRef Holsboer F, Grasser A, Friess E, Wiedemann K. Steroid effects on central neurons and implications for psychiatric and neurological disorders. Ann N Y Acad Sci. 1994;746:345–59.CrossRef
26.
go back to reference Giamberardino MA, Affaitati G, Martelletti P, Tana C, Negro A, Lapenna D, Curto M, Schiavone C, Stellin L, Cipollone F, Costantini R (2015) Impact of migraine on fibromyalgia symptoms. J Headache Pain 17:28CrossRef Giamberardino MA, Affaitati G, Martelletti P, Tana C, Negro A, Lapenna D, Curto M, Schiavone C, Stellin L, Cipollone F, Costantini R (2015) Impact of migraine on fibromyalgia symptoms. J Headache Pain 17:28CrossRef
27.
go back to reference Tana C, Santilli F, Martelletti P, di Vincenzo A, Cipollone F, Davì G, Giamberardino MA (2015) Correlation between migraine severity and cholesterol levels. Pain Pract 15(7):662–670CrossRef Tana C, Santilli F, Martelletti P, di Vincenzo A, Cipollone F, Davì G, Giamberardino MA (2015) Correlation between migraine severity and cholesterol levels. Pain Pract 15(7):662–670CrossRef
28.
go back to reference Rasmusson AM, Marx CE, Pineles SL, Locci A, Scioli-Salter ER, Nillni YI et al (2017) Neuroactive steroids and PTSD treatment. Neurosci Lett 649:156–163CrossRef Rasmusson AM, Marx CE, Pineles SL, Locci A, Scioli-Salter ER, Nillni YI et al (2017) Neuroactive steroids and PTSD treatment. Neurosci Lett 649:156–163CrossRef
Metadata
Title
Migraine and cluster headache show impaired neurosteroids patterns
Authors
Angela Koverech
Claudia Cicione
Luana Lionetto
Marta Maestri
Francesco Passariello
Elisabetta Sabbatini
Matilde Capi
Cristiano Maria De Marco
Martina Guglielmetti
Andrea Negro
Luisa Di Menna
Maurizio Simmaco
Ferdinando Nicoletti
Paolo Martelletti
Publication date
01-12-2019
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2019
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-019-1005-0

Other articles of this Issue 1/2019

The Journal of Headache and Pain 1/2019 Go to the issue